3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects
- 9 February 2012
- journal article
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 44 (1) , 61-79
Abstract
Oxidative stress-energy depletion therapy using oxidative stress induced by D-amino acid oxidase (DAO) and energy depletion induced by 3-bromopyruvate (3BP) was reported recently (El Sayed et al., Cancer Gene Ther., 19, 1–18, 2012). Even in the presence of oxygen, cancer cells oxidize glucose preferentially to produce lactate (Warburg effect) which seems vital for cancer microenvironment and progression. 3BP is a closely related structure to lactate and pyruvate and may antagonize their effects as a novel mechanism of its action. Pyruvate exerted a potent H2O2 scavenging effect to exogenous H2O2, while lactate had no scavenging effect. 3BP induced H2O2 production. Pyruvate protected against H2O2-induced C6 glioma cell death, 3BP-induced C6 glioma cell death but not against DAO/D-serine-induced cell death, while lactate had no protecting effect. Lactate and pyruvate protected against 3BP-induced C6 glioma cell death and energy depletion which were overcome with higher doses of 3BP. Lactate and pyruvate enhanced migratory power of C6 glioma which was blocked by 3BP. Pyruvate and lactate did not protect against C6 glioma cell death induced by other glycolytic inhibitors e.g. citrate (inhibitor of phosphofructokinase) and sodium fluoride (inhibitor of enolase). Serial doses of 3BP were synergistic with citrate in decreasing viability of C6 glioma cells and spheroids. Glycolysis subjected to double inhibition using 3BP with citrate depleted ATP, clonogenic power and migratory power of C6 glioma cells. 3BP induced a caspase-dependent cell death in C6 glioma. 3BP was powerful in decreasing viability of human glioblastoma multiforme cells (U373MG) and C6 glioma in a dose- and time-dependent manner.Keywords
This publication has 73 references indexed in Scilit:
- Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood PerfusionCancer Research, 2012
- Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer CellsCancer Research, 2012
- Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant CellsPLOS ONE, 2011
- Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetateOncogene, 2011
- Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3‐bromopyruvateCancer, 2009
- Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivationBiochemical Journal, 2009
- Tumor metabolism: cancer cells give and take lactateJournal of Clinical Investigation, 2008
- Lactate and malignant tumors: A therapeutic target at the end stage of glycolysisJournal of Bioenergetics and Biomembranes, 2007
- Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondriaOncogene, 2006
- On the Origin of Cancer CellsScience, 1956